Follitropin delta

Drug Profile

Follitropin delta

Alternative Names: FE-999049; Recombinant follicle-stimulating hormone - Ferring Pharmaceuticals; Recombinant FSH - Ferring; Rekovelle

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Female infertility

Most Recent Events

  • 13 Dec 2016 Registered for Female infertility in European Union (SC)
  • 13 Dec 2016 Efficacy data from the phase III ESTHER-1 trial in Female infertility released by Ferring Pharmaceuticals
  • 14 Oct 2016 Committee for Medicinal Products for Human Use (CHMP) recommends approval of follitropin delta for Female infertility in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top